AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (1291)	4/3/1998 12:51:00 AM
From: The Gambler	Read Replies (1) of 2173

Hi Henry, I am just a layman, you are the knowledgeable one, so let me ask you these: 1.You stated"..I think that the efficacy issue hangs over the finance issue which is why staff is being cut..." I'm missing something here, please explain. 2.You stated"Although some posters on this thread are convinced that Pramlintide works, JNJ obviously wasn't all that confident..."Is this a fact that you know and others on this thread are not aware of(in regards to JNJ not the posters on this thread), or is this your assumption only. Would you kindly provide statement or press release or any kind of indication from JNJ, that points to the efficacy problem as the reason why JNJ pulled out of the partnership. It would be misleading to others not knowing whether it is fact or only an assumption. BTW, thanks for your effort.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next